Elizabeth G. Nabel net worth and biography

Elizabeth Nabel Biography and Net Worth

Director of Moderna

Betsy Nabel, M.D., brings a unique perspective to health care based on her experience as a physician, research scientist, academic medicine leader, and wellness advocate. Through February 2021, Dr. Nabel was President of Brigham Health, which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization, a position she held from 2010. Simultaneous with her service as President of Brigham Health, Dr. Nabel was also a Professor of Medicine at Harvard Medical School from 2010 to 2021. Prior to joining Brigham Health, she held a variety of roles, including Director, at the National Heart, Lung and Blood Institute at the National Institutes of Health, a federal agency funding research, training and education programs to promote the prevention and treatment of heart, lung and blood diseases, from 1999 to 2009. On March 1, 2021, Dr. Nabel became the Executive Vice President for Strategy at ModeX Therapeutics, a new biotechnology company focused on developing innovative immunotherapies for cancer and viral diseases.

Her colleagues have elected her to the American Academy of the Arts and Sciences, the National Academy of Medicine, the Association of American Physicians, the American Society of Clinical Investigation, and she is a Fellow of the American Association for the Advancement of Science.

A native of St. Paul, Minnesota, Dr. Nabel attended Weill Cornell Medical College and completed her internal medicine and cardiology training at Brigham and Women’s Hospital.

What is Elizabeth G. Nabel's net worth?: The estimated net worth of Elizabeth G. Nabel is at least $2.15 million as of July 15th, 2020. Dr. Nabel owns 54,651 shares of Moderna stock worth more than $2,152,703 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Nabel may own. Learn More about Elizabeth G. Nabel's net worth.
How do I contact Elizabeth G. Nabel?: The corporate mailing address for Dr. Nabel and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on Elizabeth G. Nabel's contact information.
Has Elizabeth G. Nabel been buying or selling shares of Moderna?: Elizabeth G. Nabel has not been actively trading shares of Moderna during the last quarter. Most recently, Elizabeth G. Nabel sold 73,975 shares of the business's stock in a transaction on Wednesday, July 15th. The shares were sold at an average price of $87.84, for a transaction totalling $6,497,964.00. Following the completion of the sale, the director now directly owns 54,651 shares of the company's stock, valued at $4,800,543.84. Learn More on Elizabeth G. Nabel's trading history.
Who are Moderna's active insiders?: Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (Chief Executive Officer), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.
Are insiders buying or selling shares of Moderna?: During the last year, insiders at the sold shares 49 times. They sold a total of 647,813 shares worth more than $81,384,380.50. The most recent insider tranaction occured on December, 9th when insider Shannon Thyme Klinger sold 529 shares worth more than $23,635.72. Insiders at Moderna own 15.7% of the company. Learn More about insider trades at Moderna.
Information on this page was last updated on 12/9/2024.

Elizabeth G. Nabel Insider Trading History at Moderna

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/15/2020	Sell	73,975	$87.84	$6,497,964.00	54,651
5/12/2020	Sell	30,000	$66.00	$1,980,000.00	14,344

Elizabeth G. Nabel Buying and Selling Activity at Moderna

Moderna Company Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $39.39

$39.12

$40.83

50 Day Range

MA: $46.43

$36.85

$57.73

2 Week Range

Now: $39.39

$35.80

$170.47

Volume

35,464,590 shs

Average Volume

5,143,892 shs

Market Capitalization

$15.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW